Market	Type	Industry	Raised	Date
AIM	Acquisition	Chemicals	£12 million	Feb 2010

CONTACTS

CEO: Thomas E. D'Ambra

ADVISERS

COMMENT

Chemical specialist Excelsyn has been sold to US-based Albany Molecular Research for £12 million, providing an exit for its investors.
Excelsyn, which provides chemical development and manufacturing services to pharmaceutical companies from its headquarters in North Wales, received backing from turnaround investor Endless and regional venture capitalist NorthStar in 2007.

Related Articles

• Thermal Engineering bought by Privet Capital
• Tap into the turnaround at Harvey Nash
• Kea Petroleum goes offshore
• AMEC bags Entec
• Active merges with First Call Care

People who read this article also read ...

• HCT Group seals 'benchmark' loan deal